Vigil Neuroscience Overview
Valuation check: VIGL's ROE is -223.4%, below the sector sector average of -5.72%.
Get informed when a big investor buys or sells
+ Follow-223.40%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for VIGL is -223.4%. That is below the sector sector average of -5.72%. Investors often review this figure alongside Vigil Neuroscience's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, VIGL currently prints -223.4% for ROE, while the sector average sits near -5.72%. That is roughly 3804.0% below the sector mean. Large gaps often invite a closer look at Vigil Neuroscience's growth, margins, and balance sheet.
Return on Equity shows how effectively Vigil Neuroscience converts resources into returns. At -223.4%, VIGL may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting VIGL's ROE (-223.4%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
